Table 1.
Demographic, clinicopathologic characteristics and concentration of urinary proteins in the study cohort
| Non-cancer (%) N=63 |
cancer (%) N=64 |
||||
|---|---|---|---|---|---|
| Median Age (range, y) | 60 | (30–81) | 69.5 | (22–90) | |
| Male : Female ratio | 55 : 8 | 55 : 9 | |||
| Race | |||||
| White | 41 | (65) | 58 | (91) | |
| African American | 8 | (13) | 0 | (0) | |
| Other | 14 | (22) | 6 | (9) | |
| Tobacco use | 25 | (40) | 54 | (84) | |
| Gross hematuria | 1 | (2) | 47 | (73) | |
| Suspicious/positive cytology | 1 | (2) | 18 | (28) | |
| Median follow-up (months) | 11.5 | 12.0 | |||
| Clinical stage | |||||
| Tis^ | n/a | 6 | (9) | ||
| Ta | n/a | 15 | (23) | ||
| T1 | n/a | 9 | (14) | ||
| T2 | n/a | 31 | (48) | ||
| T3 | n/a | 4 | (6) | ||
| T4 | n/a | 2 | (3) | ||
| N+ ~ | n/a | 3 | (5) | ||
| Grade | |||||
| Low | n/a | 9 | (14) | ||
| High | n/a | 55 | (86) | ||
| Urinary Proteins | Median (range) | Median (range) | |||
| VEGF | (pg/ml) | 0 | (0 – 904.76) | 335.34 | (0 – 9841.4) |
| Angiogenin | (pg/ml) | 44.58 | (20.48–696.18) | 410.98 | (3.28 – 17944) |
| CA9 | (pg/ml) | 0 | (0 – 28.28) | 10.36 | (0 – 4132.9) |
| BTA | (U/ml) | 12.55 | (0.5 – 36.87) | 179.34 | (0 – 24865.4) |
| Hemoglobin | (ng/ml) | 0 | (0 – 125.92) | 8.73 | (0 – 130367.5) |
^
4 subjects with concomitant cis had T1 (n=2) and T2 (n=2) disease
~
Subjects with T2 (n=1), T3 (n=1) and T4 (n=1) disease and node positive